Antimicrobial Block Polypeptides for C. Difficile Spores and Biofilms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridioides difficile infections, such as vancomycin and fidaxomicin, are ineffective against spores and biofilms, leading to persistent infections and disruption of the gut microbiome, necessitating novel antimicrobials that target bacterial gastrointestinal infections while preserving the intestinal microbiota.
Innovation Solution
Development of antimicrobial block polypeptides, including linear, branched, or star-shaped polypeptides synthesized via ring-opening polymerization with biocompatible polyglycerol dendrimers, combined with enzyme-targeting macromolecules like hyaluronic acid, to target and disrupt C. difficile spores and biofilms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics (vancomycin, fidaxomicin) are used to treat C. difficile infection, then bacterial growth is inhibited, but spores and biofilms remain unaffected leading to persistent infection and microbiome disruption
Solution Approach 1:
The invention changes the chemical parameters of the antimicrobial agent by using block polypeptides with specific amino acid compositions (positively charged residues like lysine and arginine combined with hydrophobic residues) and controlled molecular weights (1,000-100,000 Da). These parameter changes enable the agent to effectively target and eliminate all forms of C. difficile including spores and biofilms, which conventional antibiotics cannot address.
Solution Approach 2:
The invention employs composite block polypeptide structures combining different amino acid blocks with distinct functions: positively charged blocks for electrostatic interaction with bacterial membranes, hydrophobic blocks for membrane penetration, and potentially enzyme-targeting blocks. This composite structure enables multi-modal action against spores, vegetative cells, and biofilms simultaneously.
2Reliability
If vancomycin is used to treat C. difficile infection, then bacterial growth is suppressed, but gut microbiome is disrupted increasing recurrence risk
Solution Approach 1:
The block polypeptide exhibits local quality through its amphiphilic structure with distinct functional blocks: positively charged regions that selectively interact with Gram-positive bacterial membranes, hydrophobic regions for membrane penetration, and controlled molecular weight for optimal penetration and activity. This localized functional differentiation enables selective toxicity toward C. difficile while sparing commensal microbiota.
Solution Approach 2:
The invention optimizes specific parameters including molecular weight (1,000-100,000 Da), amino acid composition (ratios of charged to hydrophobic residues), and block length to achieve selective antimicrobial activity. These parameter optimizations enable the agent to effectively suppress C. difficile growth while maintaining microbiome integrity, unlike conventional antibiotics.
3Reliability
If antimicrobial agents target C. difficile spores and biofilms, then persistent infection is eliminated, but treatment complexity increases
Solution Approach 1:
The block polypeptide achieves universality by being capable of targeting and eliminating all forms of C. difficile simultaneously: spores through membrane disruption, vegetative cells through membrane penetration and content leakage, and biofilms through matrix degradation and cell killing. This multi-functional capability is achieved through the polypeptide's amphiphilic structure and appropriate molecular weight, eliminating the need for combination therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antimicrobial block polypeptides effectively reduce spore numbers and biofilm formation, demonstrating potent antimicrobial activity against C. difficile, reducing recurrence risk and preserving the gut microbiome.
Implementation Method 1
a first positively charged peptide segment consisting of 5 to 20 substituted or unsubstituted amino acids selected from the group consisting of L-lysine, L-arginine, L-histidine L-omithine, and L-homoarginine
Data Source
AI summary
The present invention discloses an antimicrobial block polypeptide, a therapeutic composition comprising the antimicrobial block polypeptide, and a method for treating bacterial gastrointestinal infection by administering the therapeutic composition. Antimicrobial block polypeptide comprises a first positively charged peptide segment demonstrating potent sporicidal effects on gastrointestinal infectious bacteria. The therapeutic composition may further contain an enzyme-targeting macromolecule, where the antimicrobial block polypeptide docks on negatively charged functional group thereof. Such enzyme-targeting macromolecule-based therapeutic agent delivery system enhances sustainability of the antimicrobial block polypeptide in the body of a subject when administered orally. Moreover, the antimicrobial block polypeptide is capable of suppressing bacterial gastrointestinal infection without disrupting intestinal microbiota.